Kiora Pharmaceuticals (KPRX) Expected to Announce Quarterly Earnings on Tuesday

Kiora Pharmaceuticals (NASDAQ:KPRX) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $1.50 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Kiora Pharmaceuticals Trading Down 2.4%

Shares of NASDAQ:KPRX opened at $2.04 on Tuesday. The stock has a fifty day simple moving average of $2.13 and a two-hundred day simple moving average of $2.26. Kiora Pharmaceuticals has a 12-month low of $1.76 and a 12-month high of $4.18. The stock has a market capitalization of $7.51 million, a price-to-earnings ratio of -0.98 and a beta of -0.80.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. DRW Securities LLC boosted its holdings in Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after purchasing an additional 73,417 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Kiora Pharmaceuticals during the 4th quarter valued at $152,000. Citadel Advisors LLC purchased a new stake in Kiora Pharmaceuticals during the 3rd quarter valued at $125,000. Renaissance Technologies LLC lifted its holdings in shares of Kiora Pharmaceuticals by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after buying an additional 8,800 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Kiora Pharmaceuticals during the 3rd quarter valued at $33,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Wednesday, January 28th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.